BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 25976012)

  • 1. Factor XI and contact activation as targets for antithrombotic therapy.
    Gailani D; Bane CE; Gruber A
    J Thromb Haemost; 2015 Aug; 13(8):1383-95. PubMed ID: 25976012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rebirth of the contact pathway: a new therapeutic target.
    Srivastava P; Gailani D
    Curr Opin Hematol; 2020 Sep; 27(5):311-319. PubMed ID: 32740037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting factor XI and factor XIa to prevent thrombosis.
    Gailani D; Gruber A
    Blood; 2024 Apr; 143(15):1465-1475. PubMed ID: 38142404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor XI as a Therapeutic Target.
    Gailani D; Gruber A
    Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1316-22. PubMed ID: 27174099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.
    Tillman B; Gailani D
    Semin Thromb Hemost; 2018 Feb; 44(1):60-69. PubMed ID: 28898903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants.
    Weitz JI; Fredenburgh JC
    Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):304-310. PubMed ID: 29269514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives.
    Vlădăreanu AM; Roşca A
    Rom J Intern Med; 2024 Jun; 62(2):91-100. PubMed ID: 38153875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates.
    Puy C; Tucker EI; Wong ZC; Gailani D; Smith SA; Choi SH; Morrissey JH; Gruber A; McCarty OJ
    J Thromb Haemost; 2013 Jul; 11(7):1341-52. PubMed ID: 23659638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor XI and factor XII as targets for new anticoagulants.
    Weitz JI
    Thromb Res; 2016 May; 141 Suppl 2():S40-5. PubMed ID: 27207423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
    Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hemostatic role of factor XI.
    Puy C; Rigg RA; McCarty OJ
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S8-S11. PubMed ID: 27207433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor XI and XII as antithrombotic targets.
    Müller F; Gailani D; Renné T
    Curr Opin Hematol; 2011 Sep; 18(5):349-55. PubMed ID: 21730835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic pathway of coagulation and arterial thrombosis.
    Gailani D; Renné T
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2507-13. PubMed ID: 17916770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coagulation factor XI as a novel target for antithrombotic treatment.
    Löwenberg EC; Meijers JC; Monia BP; Levi M
    J Thromb Haemost; 2010 Nov; 8(11):2349-57. PubMed ID: 20727068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials.
    DeLoughery EP; Olson SR; Puy C; McCarty OJT; Shatzel JJ
    Semin Thromb Hemost; 2019 Jul; 45(5):502-508. PubMed ID: 31216587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol stents under flow.
    Keeling NM; Wallisch M; Johnson J; Le HH; Vu HH; Jordan KR; Puy C; Tucker EI; Nguyen KP; McCarty OJT; Aslan JE; Hinds MT; Anderson DEJ
    J Thromb Haemost; 2024 May; 22(5):1433-1446. PubMed ID: 38331196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors IX, XI, and XII: potential therapeutic targets for anticoagulant therapy in atherothrombosis.
    Rai V; Balters MW; Agrawal DK
    Rev Cardiovasc Med; 2019 Dec; 20(4):245-253. PubMed ID: 31912715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates.
    Crosby JR; Marzec U; Revenko AS; Zhao C; Gao D; Matafonov A; Gailani D; MacLeod AR; Tucker EI; Gruber A; Hanson SR; Monia BP
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1670-8. PubMed ID: 23559626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulation factors XI and XII as possible targets for anticoagulant therapy.
    Kluge KE; Seljeflot I; Arnesen H; Jensen T; Halvorsen S; Helseth R
    Thromb Res; 2022 Jun; 214():53-62. PubMed ID: 35490644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor XI contributes to thrombin generation in the absence of factor XII.
    Kravtsov DV; Matafonov A; Tucker EI; Sun MF; Walsh PN; Gruber A; Gailani D
    Blood; 2009 Jul; 114(2):452-8. PubMed ID: 19351955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.